Dyne Therapeutics, Inc. (DYN)
|Net Income (ttm)||n/a|
|Trading Day||February 25|
|Day's Range||19.10 - 20.86|
|52-Week Range||15.60 - 32.32|
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people livi...
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -
Dyne Therapeutics, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
Pharmaceutical Preparation Manufacturing
|IPO Date |
Sep 17, 2020
Joshua T. Brumm
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 36.40, which is an increase of 87.63% from the latest price.